Gastro Relief

AOR04201

Promotes gastric health

  • Heals and protects gastric lining
  • Provides fast-acting relief of heartburn, indigestion and gastritis
  • Protects the esophagus
  • Kills H. pylori bacteria
  • Relieves symptoms of acid reflux while addressing possible causes
Gluten Free
Non-GMO
Vegan

$44.94 or subscribe and save 20%

In stock

Choose a purchase plan:
If you decide a subscription is not for you, it can be cancelled after 30 days.

Gastro Relief is a revolutionary supplement for heartburn, indigestion, gastritis and other conditions of the upper gastrointestinal tract. It is designed to quickly and effectively provide natural support against the pain of heartburn while providing nutrients that target its potential causes. In addition, it helps heal the lining of the stomach. Many people suffer from heartburn or acid indigestion caused by acid reflux.

Each ingredient of Gastro Relief has a purpose. Mastic gum has been shown to disable Helicobacter pylori (H. pylori), a species of bacteria that is at the root of many heartburn cases and ulcers. Vitamin C increases the acidity of the stomach; most gastric issues stem from a lack of stomach acid as opposed to too much. Ginger calms the stomach during digestive upset, while zinc-carnosine and nitric oxide promote the healing of damaged stomach lining cells. Finally, sodium alginate prevents gastric contents from backing up into the esophagus, preventing painful heartburn symptoms and protecting the esophagus against damage from acidity.

AOR Advantage

AOR’s Gastro Relief is one of the few products containing sodium alginate, an effective, fast acting and research-supported therapy for acid reflux symptoms. AOR’s rigorous sourcing processes, and in-house production capacity allow for a more comprehensive formulation and an innovative advantage.

NPN

80033385

Discussion

Gastro Relief helps relieve digestive upset/disturbances including dyspepsia.

Guarantees

AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, nuts, peanuts, sesame seeds, mustard, soy, dairy, eggs, fish, shellfish or any animal byproduct.

Adult Dosage

Take two capsules daily with food, or as directed by a qualified health care practitioner.

Cautions

Consult a health care practitioner if symptoms persist or worsen. Hypersensitivity (ie. allergy) has been known to occur, in which case discontinue use. Methemoglobinemia has been reported on rare occasions following an accidental overdose of potassium nitrate; intravenous methylene blue is the specific therapy for this condition. This product contains corn derived ingredients, do not use if you have an allergy.

Do not use if pregnant or breastfeeding, if you are taking erectile dysfunction-type products, or if you have an allergy to plants of the Anacardiaceae family such as pistachio, terebinth, Chinese pistache, and Schinus terebinthifolius (Brazilian pepper). Consult a health care practitioner prior to use if you have hypochlorhydria/achlorhydria, stomach lesions, diabetes mellitus, Crohn’s disease, or if you are taking hypoglycemic agents or hypolipidemic agents.

Main Applications
  • Esophageal distress
  • Digestive upset
Disclaimer

The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.

Serving Size: Two Capsules
Zingiber officinale extract (Ginger)
50 mg
Zinc L-Carnosine
75 mg
Pistacia lentiscus (Mastic gum)
400 mg
Vitamin C (ascorbic acid)
100 mg

Non-medicinal Ingredients: Potassium nitrate (202 mg), sodium alginate, microcrystalline cellulose, silicon dioxide, sodium stearyl fumarate, maltodextrin, calcium carbonate, calcium chloride, hydrochloric acid and sodium hydroxide.

Capsule: hypromellose.

Promotes Healing of Stomach Ulcers

Study #1:

Zinc is perhaps best known for its approved use in Japan for the management of stomach ulcers. In a randomized, controlled, double-blind study, 258 subjects with confirmed stomach ulcers were randomly assigned to receive 150 mg zinc per day, a placebo, 800 mg of cetraxate hydrochloride (a known mucosal protection agent), or its placebo for eight weeks. Endoscopy was done before and after treatment and subjective measures of symptoms were collected. Symptoms were 61% better in the marked improvement category in the zinc group and 61.5% in the cetraxate group at four weeks. At eight weeks, the zinc group increased to 75% markedly improved compared to 72% for the cetraxate group. The endoscopic cure rate was 26.3% in the zinc group and 16.2% in the cetraxate group at four weeks and 60.4% in the zinc group and 46.2% in the cetraxate group at eight weeks. This suggests that zinc can provide superior relief of symptoms and improvement in gastric ulcers compared to a known mucosal protection agent.

Miyoshi A., Namiki A., Asagi S., Harasawa S., Ooshiba S., Hayakawa K. Clinical Evaluation of Z-103 on Gastric Ulcer–A Multicenter Double-Blind Comparative Study with Cetraxate Hydrochloride. Jpn. Pharm. Ther. 1992;20:199–223

Study #2:

A 1984, double-blind clinical trial investigated the treatment of duodenal ulcer with mastic and placebo in thirty-eight patients with symptomatic and endoscopically proven duodenal ulcer. The trial aimed to compare the therapeutic responses to mastic (1 g daily, twenty patients) and placebo (lactose, 1 g daily, eighteen patients) given orally over a period of two weeks. Symptomatic relief was obtained in sixteen (80%) patients on mastic and in nine (50%) patients on placebo, while endoscopically proven healing occurred in fourteen (70%) patients on mastic and four (22%) patients on placebo. The differences between treatments were highly significant (P less than 0.01). Mastic was well tolerated and did not produce side effects. The researchers concluded that mastic has an ulcer healing effect, but further studies are needed to establish its role in treating peptic ulcer.

Al-Habbal MJ, Al-Habbal Z, Huwez FU. A double-blind controlled clinical trial of mastic and placebo in the treatment of duodenal ulcer. Clin Exp Pharmacol Physiol. 1984;11(5):541-544. doi:10.1111/j.1440-1681.1984.tb00864.x https://pubmed.ncbi.nlm.nih.gov/6395994/

Study #3:

In this 1986 study, the effect of mastic, a concrete resinous exudate obtained from the stem of the tree Pistacia lentiscus, has been studied on experimentally-induced gastric and duodenal ulcers in rats. Mastic at an oral dose of 500 mg/kg produced a significant reduction in the intensity of gastric mucosal damage induced by pyloric ligation, aspirin, phenylbutazone, reserpine and restraint + cold stress. It produced a significant decrease of free acidity in 6-h pylorus-ligated rats and a marked cytoprotective effect against 50% ethanol in rats which could be reversed by prior treatment with indomethacin. The protective effect was not seen when it was given intraperitoneally in phenylbutazone and restraint + cold stress models. The reduction in the intensity of ulceration in cysteamine-induced duodenal ulcers was not found to be statistically significant in mastic-pretreated rats. The results suggest that mild antisecretory and a localized adaptive cytoprotectant action may be responsible for its anti-ulcer activity. These observations support the results of an earlier study on the clinical effectiveness of mastic in the therapy of duodenal ulcer.

Al-Said MS, Ageel AM, Parmar NS, Tariq M. Evaluation of mastic, a crude drug obtained from Pistacia lentiscus for gastric and duodenal anti-ulcer activity. J Ethnopharmacol. 1986;15(3):271-278. doi:10.1016/0378-8741(86)90165-0 https://pubmed.ncbi.nlm.nih.gov/3724207/

Treatment of Mucositis

Oral mucositis is a common complication of cytotoxic radiotherapy and/or chemotherapy. It occurs in almost every person with head and neck cancer who receive radiotherapy. It is often overlooked because it is not considered life threatening. However, mucositis often leads to a decreased quality of life and cessation of treatment, ultimately decreasing positive outcomes.

Hewlings S, Kalman D. A Review of Zinc-L-Carnosine and Its Positive Effects on Oral Mucositis, Taste Disorders, and Gastrointestinal Disorders. Nutrients. 2020;12(3):665. Published 2020 Feb 29. doi:10.3390/nu12030665 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146259/

Treatment of Taste Disorders (Ageusia)

Study #1:

In a 2009, randomized, double-blind, placebo-controlled trial, multi-center study, the effect of zinc on taste disorders was assessed. In total, 107 subjects suffering from taste disorders not associated with cancer were assigned to receive placebo, 75 mg, 150 mg, or 300 mg of zinc orally for 12 weeks. Taste perception was assessed using the paper filter disk (PFD) and a subjective questionnaire and serum zinc were measured before and after supplementation. Subjects receiving the 300 mg dose demonstrated a significant improvement compared to the placebo group. Subjective report symptoms improved in the groups receiving the 150 mg and 300 mg doses. Serum zinc increased in a dose-dependent manner, with the group that received the highest dose of zinc demonstrating a statistically significant increase from baseline. No serious adverse events were reported.

Sakagami M., Ikeda M., Tomita H., Ikui A., Aiba T., Takeda N., Inokuchi A., Kurono Y., Nakashima M., Shibasaki Y. A zinc-containing compound, Polaprezinc, is effective for patients with taste disorders: Randomized, double-blind, placebo-controlled, multi-center study. Acta Oto Laryngol. 2009;129:1115–1120. doi: 10.1080/00016480802552550 https://pubmed.ncbi.nlm.nih.gov/19037756/

Study #2:

Another study was conducted to assess the effect of 150 mg of zinc supplementation in 40 patients complaining of taste impairment. The patients were screened for serum zinc levels and divided into two groups. The zinc-deficient taste disorder group were those with serum zinc of less than 63 µg/dl with no history of other disorders; those with values higher than that were placed in the idiopathic group. Both groups received 150 mg of zinc for an average of 17.7 weeks. Subjective symptoms were measured via the visual analogue scale (VAS). There were no statistically significant differences in subjective symptoms between the groups at baseline. Interestingly, supplementation improved symptoms significantly in both groups. There were no correlations between the VAS scores and serum zinc levels at the end of the study, suggesting that zinc deficiency or impairment may be present even when serum zinc levels are not below recommended levels.

Takaoka T., Sarukura N., Ueda C., Kitamura Y., Kalubi B., Toda N., Abe K., Yamamoto S., Takeda N. Effects of zinc supplementation on serum zinc concentration and ratio of apo/holo-activities of angiotensin converting enzyme in patients with taste impairment. Auris Nasus Larynx. 2010;37:190–194. doi: 10.1016/j.anl.2009.07.003 https://pubmed.ncbi.nlm.nih.gov/19716667/

Treatment of Functional Dyspepsia

Study #1:

A 2010, prospective randomised double-blind placebo-controlled trial assessed the efficacy of Chios mastic gum in patients with functional dyspepsia. One hundred and forty-eight patients fulfilling Rome II criteria for functional dyspepsia were randomly assigned to receive either Chios mastic gum 350 mg three times daily or placebo. After 3 weeks of treatment the change from baseline in the severity of symptoms of functional dyspepsia was assessed using the Hong Kong index of dyspepsia. Patients’ global assessment of efficacy was also evaluated.

Results: The symptom score after treatment was significantly lower in the Chios mastic gum than in the placebo group ((14.78+/-1.78) vs (19.96+/-1.83)) (p<0.05). There was a marked improvement of symptoms in 40% of patients receiving placebo and in 77% of patients receiving Chios mastic gum (p<0.02). Individual symptoms that showed significant improvement with Chios mastic gum were: stomach pain in general, stomach pain when anxious, dull ache in the upper abdomen and heartburn (<0.05 for all four symptoms). The researchers concluded that Chios mastic gum significantly improves symptoms in patients with functional dyspepsia compared to placebo.

Dabos KJ, Sfika E, Vlatta LJ, Frantzi D, Amygdalos GI, Giannikopoulos G. Is Chios mastic gum effective in the treatment of functional dyspepsia? A prospective randomised double-blind placebo-controlled trial. J Ethnopharmacol. 2010;127(2):205-209. doi:10.1016/j.jep.2009.11.021 https://pubmed.ncbi.nlm.nih.gov/19961914/

Helicobacter pylori Eradication

Study #1:

In this 2009, randomized, pilot study, the researchers studied the effect of pure mastic gum on Helicobacter pylori (H. pylori) eradication in patients suffering from an H. pylori infection. Fifty two patients were randomized to receive either 350 mg three times a day (tid) of pure mastic gum for 14 days (Group A), or 1.05 g tid of pure mastic gum (Group B) for 14 days, or pantoprazole 20 mg twice a day (bd) plus pure mastic gum 350 mg tid for 14 days (Group C) or pantoprazole 20 mg bd plus amoxicillin 1g bd plus clarithromycin 500mg bd for 10 days (Group D). All patients harboured H. pylori before entering the study and that was confirmed by a (13)C urea breath test (UBT). H. pylori eradication was tested by a UBT 5 weeks after completion of the eradication regime. Eradication of H. pylori was confirmed in 4/13 patients in Group A and in 5/13 in Group B. No patient in Group C achieved eradication whereas 10/13 patients in Group D had a negative UBT. There were no statistically significant differences in mean UBT values in Groups A, B, C although there was a trend in Group A (p=0.08) and in Group B (p=0.064). The difference was significant in Group D (p=0.01). All patients tolerated mastic gum well and no serious adverse events were reported. Mastic gum has bactericidal activity on H. pylori in vivo.

Dabos KJ, Sfika E, Vlatta LJ, Giannikopoulos G. The effect of mastic gum on Helicobacter pylori: a randomized pilot study. Phytomedicine. 2010;17(3-4):296-299. doi:10.1016/j.phymed.2009.09.010 https://pubmed.ncbi.nlm.nih.gov/19879118/

Study #2:

In this 2007 study, the extract and pure major constituents of Chios mastic gum (resin of Pistacia lentiscus var. chia) were tested for their activities against Helicobacter pylori in vivo in mice and in vitro. A total mastic extract without polymer (TMEWP) was prepared after removal of the contained insoluble polymer in order to ameliorate solubility and enhance in vivo activity. Administration of TMEWP to H. pylori SS1-infected mice over the period of three months with an average dose of 0.75 mg/day led to an approximately 30-fold reduction in the H. pylori colonization (1.5 log CFU/g of tissue). However, no attenuation in the H. pylori-associated chronic inflammatory infiltration and the activity of chronic gastritis was observed. To further characterize potential active mastic constituents, the TMEWP was separated into an acidic and a neutral fraction. Both were extensively characterized by nuclear magnetic resonance and mass spectroscopy to elucidate the structure of the components contained within each fraction. After chromatographic separation, the acid fraction gave the major triterpenic acids, while the neutral fraction gave several triterpenic alcohols and aldehydes. Mastic extracts and isolated pure triterpenic acids were tested for in vitro activity against a panel of 11 H. pylori clinical strains. The acid fraction was found to be the most active extract (minimum bactericidal concentration [MBC], 0.139 mg/ml), and the most active pure compound was isomasticadienolic acid (MBC, 0.202 mg/ml [0.443 mM]). Our results show that administration of TMEWP may be effective in reducing H. pylori colonization and that the major triterpenic acids in the acid extract may be responsible for such an activity.

Paraschos S, Magiatis P, Mitakou S, et al. In vitro and in vivo activities of Chios mastic gum extracts and constituents against Helicobacter pylori. Antimicrob Agents Chemother. 2007;51(2):551-559. doi:10.1128/AAC.00642-06 https://pubmed.ncbi.nlm.nih.gov/17116667/

Study #3:

The gingerols are a group of structurally related polyphenolic compounds isolated from ginger and known to be the active constituents. Since Helicobacter pylori (HP) is the primary etiological agent associated with dyspepsia, peptic ulcer disease and the development of gastric and colon cancer, the anti-HP effects of ginger and its constituents were tested in vitro.

In this study, a methanol extract of the dried powdered ginger rhizome, fractions of the extract and the isolated constituents, 6-,8-, 10-gingerol and 6-shogoal, were tested against 19 strains of HP, including five  CagA+ strains. The methanol extract of ginger rhizome inhibited the growth of all 19 strains in vitro with a minimum inhibitory concentration range of 6.25–50 µg/ml. One fraction of the crude extract, containing the gingerols, was active and inhibited the growth of all HP strains with an MIC range of 0.78 to 12.5 µg/ml and with significant activity against the CagA+ strains.

This data demonstrates that ginger root extracts containing the gingerols inhibit the growth of H. pylori CagA+ strains in vitro and this activity may contribute to its chemopreventative effects.

Mahady GB, Pendland SL, Yun GS, Lu ZZ, Stoia A. Ginger (Zingiber officinale Roscoe) and the gingerols inhibit the growth of Cag A+ strains of Helicobacter pylori. Anticancer Res. 2003;23(5A):3699-3702. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3761965/

Study #4:

This pilot study study aimed to assess the effect of ginger (Zingiber officinale) powder supplementation on Helicobacter pylori eradication and improvement of dyspeptic symptoms in 15 patients with H. pylori positive functional dyspepsia (FD). Each patient received 3 g/d ginger powder as three 1 g tablets for four weeks. Dyspepsia symptoms were asked before and after the intervention using a questionnaire based on the Rome III criteria. H. pylori eradication was also assessed by a non-invasive stool antigen (HpSAg) test.

Ginger consumption accompanied by significant H. pylori eradication rate of 53.3% (P = 0.019) and the odds ratio (95% CI) was eight (1.07 to 357.14). Moreover, the results showed significant changes in most of the dyspepsia symptoms after ginger supplementation. According to the findings, Z. officinale can be considered as a useful complementary therapy for FD. However, due to the small number of clinical trials in this area, further well-designed clinical trials are needed to explicitly talk about its effectiveness especially about the eradication of H. pylori.

Ebrahimzadeh Attari V, Somi MH, Asghari Jafarabadi M, Ostadrahimi A, Moaddab SY, Lotfi N. The Gastro-protective Effect of Ginger (Zingiber officinale Roscoe) in Helicobacter pylori Positive Functional Dyspepsia. Adv Pharm Bull. 2019;9(2):321-324. doi:10.15171/apb.2019.038 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6664109/